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Abstract
At the symposium, approaches to individualized cancer medicine were considered, from basic sciences (genetics,
epigenetics, biological tumor signatures) to clinical investigations, including strategies about how best to under-
take the clinical development of targeted agents.
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The conference was opened by Enrico Mihich, thanking Edison Liu
(local host) and Kurt S. Zaenker, co-chair of the International Scien-
tific Organizing Committee, and the members of the Local Organiz-
ing Committee (Sir David Lane, Alex Matter, Michael Roßbach) for
developing the scientific program and for working to help him create
this symposium on personalized cancer medicine. Hans-Peter Huber
(board member, Fritz-Bender-Foundation) gave a warm welcome
wishing a successful conference. Edison Liu, executive director, Genome
Institute of Singapore, followed with welcoming remarks from the host
institution and pointed out that personalized medicine is the manage-
ment of health and the treatment of diseases, which is specific for the
genetic and epigenetic makeup of an individual. The challenges are
great because there are no historical models, but the opportunities for
discovery and innovation are significant.
The symposium was divided into 5 sessions: I) Cancer Genetics
(chaired by E. Liu), II) Genetic Mutations I (chaired by Sin Tiong
Ong), III) Gene Expression Regulation (chaired by Carl Novina), IV)
Disease-Specific Concerns (chaired by Frank McKeon), and V) Genetic
Mutations II (chaired by Richard Gaynor/Kurt S. Zaenker).
Session I: Cancer Genetics
E. Liu (Singapore, Singapore) stated that the key of personalized cancer
medicine will be to find the modes of control, for the driving mutations
in cancer cells to effectively shut them down. Understanding the ge-
nomic instability, the transcriptional and functional consequences
and to find new, robust and predictive biomarkers and tumor targets
will be the key efforts as we move toward tailoring specific therapies for
cancer. Many transcription factors bind to regulatory DNA elements
distant from gene promoters, and his group found that remote estrogen
receptor α-binding sites are anchored at gene promoters through long-
range chromatin interactions. This finding suggests that estrogen recep-
tor α functions as an extensive chromatin loop to bring genes together
for coordinated transcriptional regulation. In general, to map functional
elements for genomic rearrangements—amplifications, deletions, inser-
tions, inversions, translocations—will require accurate interrogation
and comparison of individual human genomes and genomic structures
at appropriate and affordable costs. An immediate and widely recog-
nized solution is the DNA paired end ditag (DNA PET), a cloning
strategy where paired ends of genomic fragments of specific length
(1, 5, and 10 kb) are cloned and isolated for sequencing using next-
generation technologies (Genome Res. 2007;17[6]:828–832). His group
sequenced a total of 111 million PETs from three MCF-7 libraries and
identified about 2400 clusters where the mapping of the PETs showed
significant deviation from the reference genome. When the potential
for fusion genes was assessed, they found approximately 753 intrachro-
mosomal events that may generate a potential fusion gene and 31 inter-
chromosomal rearrangements that might be potential fusion genes.
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Y. Zeng (Guangzhou, China) talked about the nasopharyngeal car-
cinoma (NPC)—a very prevalent malignancy in south China—as a
model for translational and personalized medicine. Personalized med-
icine also means to identify the right patient, at the right time, and
for the right treatment. The major clinical needs for the NPC are as
follows: (i) to prevent by developing appropriate vaccines and vaccination
strategies, (ii) to identify high-risk populations and early diagnosis, iii)
to classify the molecular signature of the tumor for personalized treat-
ment, and (iv) last but not least, to develop supportive treatment. His
group has recently shown that glycosylated serglycin regulates NPC
metastasis via autocrine and paracrine routes and that it serves as a
prognostic marker of metastasis-free survival and disease-free survival
in NPC patients. Moreover, they have strengthened the belief that
MMP-9 mRNA expression in peripheral blood mononuclear cells
is increased in NPC patients and may contribute to the progression
of NPC.
Session II: Genetic Mutations
S.T. Ong (Singapore, Singapore). The oncogenic kinase Bcr-Abl is
thought to cause chronic myelogenous leukemia (CML) by altering
the transcription of specific genes with growth- and survival-promoting
functions. Bcr-Abl has also been shown to activate an important regula-
tor of protein synthesis, the mammalian target of rapamycin (mTOR),
which suggests that dysregulated translation may also contribute to dis-
ease progression. Blast crisis is a deadly event in CML, and they found
within the blast crisis that both Bcr-Abl and the mTORC1 complex
contribute to the phosphorylation and inactivation of 4E-PB1, an in-
hibitor of the eIF4E translation initiation factor. One target transcript is
cyclin D3, which is increased in Bcr-Abl–expressing cells. It was found
that the combination of imatinib and rapamycin acts synergistically
against committed CML progenitors from chronic and blast phase
patients. A new drug, CGP 57380, is under evaluation in blast crisis
patients.
E. Collisson (San Francisco, CA). Pancreatic ductal adenocarci-
noma (PDA) is an invariably lethal disease, without any screening
methods. At the time of diagnosis, more than 80% of the patients
present themselves with an unresectable tumor, and the incidence
rate almost equals the mortality rate. His group has defined three
subtypes of PDA: i) acinar cell, ii) mesenchymal, and iii) epithelial
forms. Outcome and therapeutic response is much better in the ep-
ithelial than in the mesenchymal subtype. The frequently mutated
genes in PDA are K-ras2, p16/CDKN2a, TP53, and DPC4/MADA4.
PDA also show a high rate of desmoplastic reaction. GATA6, a tran-
scriptional regulator, is linked to normal pancreas development. When
amplified and aberrantly expressed, it contributes to PDA develop-
ment. GATA6 and several other subtype markers can be used to stratify
patients for treatment together with preclinical systems that can be used
as models in which to identify new subtype-specific therapies.
Y. Ruan (Singapore, Singapore). Somatic genome rearrangements
are thought to play an important role in cancer development. Character-
ization of all the functional components constituted in human genome
relies on the ability to completely elucidate the genetic/epigenetic reg-
ulatory networks, chromatin states, nuclear architectures, and genome
variations. Pair end ditag–based sequencing concept was conceived as
an immediate solution to expand the information content and extend
the linear coverage. Features of PET strategy have the potential to revo-
lutionize the approaches used to decipher regulatory networks in system
biology, define the genome organization, and characterize genome var-
iations, which ultimately leads to the development of strategies for per-
sonalized medicine (Wiley Interdiscip Rev Syst Biol Med. 2010;2[2]:
224–234).
J. Wang (Shenzhen, China). Dr. Wang Jun, executive director
of BGI, spoke on genetic analysis of cancers and cancer progression
using single-cell sequencing. He introduced the Beijing Genomics
Institute (BGI), one of the premier genome sequencing centers in
the world, with locations in Hong Kong, Hangzhou, Beijing, Boston,
and Copenhagen. The genomic landscape shows marked variations in
the distribution of a number of features, including genes, transposable
elements, CC content, CpC islands, and recombination rate. In tu-
mors, there seem to be 5262 high-confidence mutated genes, and by
single-cell sequencing, they could determine six subgroups of cells in
AML. More than 1.4 million nucleotide polymorphisms (SNPs) in
the human genome have been identified, and the identification of
genome-wide SNP genotypes in human tumors may contribute to iden-
tify subgroups of patients undergoing successful therapeutic regimens.
Session III: Gene Expression Regulation
C. Novina (Boston, MA). In the human genome, up to now, approx-
imately 1000 microRNAs are known, which are involved in the regu-
lation of cell differentiation, proliferation, and apoptosis. MicroRNAs
are an ancient gene expression regulatory system, are cotranslational
gene regulators at the posttranslational level, and bind to mRNAs,
yet the mechanisms to repress the translation of target mRNAs are ob-
scure. His group observed that miRNA-targeted mRNAs are enriched
for 40S but not 60S ribosome components. The results suggest that
miRNA represses translation initiation by preventing 60S subunit join-
ing to miRNA target mRNAs (Proc Natl Acad Sci USA. 2008;105
[14]:5343–5348). His group found that tumor-suppressive activity is
mediated by miR-211 hosted within an intron of melastatin, a mela-
noma tumor suppressor. Increasing the expression of miR-211 reduced
migration and invasion of malignant and highly invasive human mela-
nomas characterized by low levels of melastatin and miR-211. Further-
more, the expression of three node genes, namely, IGF2R, TGFBR2,
and NFAT5, was reduced by miR-211. Their data show that intronic
miR-211 accomplishes the tumor-suppressive function via suppression
of the entire melastatin locus during human melanoma progression.
F. Slack (New Haven, CT). Some miRNAs, referred to as
oncomiRNAs, show differential expression levels in cancer and are
able to affect cellular transformation, carcinogenesis, and metastasis,
acting either as oncogenes or as tumor suppressors. In A549 lung cancer
cells, inhibiting let-7 function leads to increased cell division, whereas
overexpression of let-7 in cancer cell lines alters cell cycle progression
and reduces cell division. His group showed that let-7 miRNAs controls
expression of RAS. Let-7 expression is lower in lung cancer tumors than
in normal lung tissues, whereas RAS protein is higher in lung tumors. It
was shown that let-7 miRNA is a master regulator of cell proliferation
pathways. Targeting RAS with a miRNA in lung cancer was success-
fully carried out in vivo and slowed down the growth behavior. This
was the first time that any miRNA has been shown to have therapeutic
efficacy in vivo in cancer. His group also identified an SNP in KRAS 3′
UTR that disrupts a let-7 miRNA complementary site and is associated
with a two-fold increased risk of developing lung cancer, therefore char-
acterizing the first solid genetic marker for inherited lung cancer risk.
Sir David Lane (Singapore, Singapore). p53 is considered the
most significant of all the genes altered in cancer cells because muta-
tions of this gene are known to cause almost 50% of all human can-
cers. Therefore, the key question is what can be done in those cases
where p53 is mutated? One approach is the search for molecules that
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will chaperone mutant p53 to fold in the active state. Furthermore,
small molecules that activate the transcriptional function of wild-type
p53 have proven active as anticancer drugs in preclinical models, and
clinical trials are on the way; among them are Mdm2 inhibitors,
kinase inhibitors, a sirtuin inhibitor, and low doses of actinomycin
D. It is likely that a cocktail of such molecules addresses differentially
the complexity of the upstream p53 signaling pathways to gain func-
tion of wild-type p53. The concept further works out for chemopro-
tection. Normal cells are arrested temporarily in the G1 phase by p53
activators such as the Mdm2 inhibitor Nutlin. These cells are thus
protected from cytotoxic drugs active in the G2/M phase such as
taxol. Cells that lack p53 and are therefore not arrested by Nutlin
would retain their sensitivity. In this model, the therapeutic index
of such cytotoxic drugs for p53 mutant tumor would be enhanced
by the protection of normal tissues.
S. Baylin (Baltimore, MD). He spoke on the potential for epige-
netic therapy as a contribution to the personalized management of
cancer. Among the best understood of the abnormalities that consti-
tute “cancer epigenome” is the aberrant transcriptional repression
and, often associated, DNA hypermethylation of gene promoter
CpG islands. This change was associated with hundreds of genes in
every cancer type and in every patient’s tumor. The gains of DNA
hypermethylation occur simultaneously with losses of DNA methyl-
ation in nonpromoter regions and in promoters that lack CpG island.
Cells exposed to increases in reactive oxygen species show a rapid in-
duction of a large complex of proteins that target away from the re-
gions of loss of DNA methylation and to gene promoter CpG islands.
The formation of this complex, which contains DNA methyltrans-
ferases and polycomb proteins, becomes a key candidate mechanism
for the range of DNA methylation abnormalities seen in cancer. Drug
development comes at a time when existing DNA-hypomethylating
and histone deacetylase–inhibiting drugs are beginning to gain attrac-
tion for clinicians for most common human tumors, such as lung can-
cer. Combination therapy with vidaza, a DNA demethylation agent,
and entinostat, a histone deacetylase inhibitor, was shown to suppress
tumor growth and reprogram the epigenome in an orthotopic lung
cancer model (Cancer Res. 2011;71[2]:454–462).
Session IV: Disease-Specific Concerns
F. McKeon and W. Xian (Singapore, Singapore) spoke on esophageal
and gastric adenocarcinoma, which arise in association with chronic
inflammation triggered in the case of gastric cancer (GC) by Helico-
bacter pylori infections and in esophageal adenocarcinoma by the
seemingly benign bouts of acid reflux. The premalignant lesions in
both of these cancers are strikingly similar and generally termed “in-
testinal metaplasia.” Both groups are working with a mouse model in
an attempt to mimic the damage to the squamous epithelia typical of
acid reflux. They precisely defined the cellular origin of these meta-
plasias and have demonstrated that such cells exist in a dormant state
at the squamocolumnar junction and—getting an activating cue—
move (“stem cell–like”) into the tissue, thereby destroying the epi-
thelial lining in both healthy mice and humans. Both groups are
presently exploiting the gene expression data sets of such dormant
cells to test the possibility that these junctional embryonic cells are
the source of Barrett metaplasia and whether similar cells exist in gas-
tric epithelia as well.
E. Dolan (Chicago, IL) addressed the problem of many patients
undergoing chemotherapy with the risk of severe toxicities, yet never
experience a tumor response by searching for pharmacogenomic
markers. The model uses lymphoblastoid cell lines derived from in-
dividuals within different world populations (white, African, Asian,
African Americans). These cell lines are rich in genetic data because
many are part of the international HapMap cell lines (Am J Hum
Genet. 2010;87[6]:829–833). Therefore, they can be used for phar-
macologic phenotyping to identify SNPs associated with drug sen-
sitivity. There were several hundred SNPs associated with each
chemotherapeutic drug (cisplatin, carboplatin, daunorubicin, etopo-
side, cytoarabine) within each population (interindividual and inter-
ethnic differences). Her group found that the chemotherapeutic
susceptibility-associated SNPs are more likely to be eQTLs (quanti-
tative trait locus) and in fact more likely to be associated with the
transcriptional expression level of multiple genes as potential master
regulators compared to a random set of SNPs in the genome.
A.L Borresen-Dale (Oslo, Norway) spoke about the basic biology
and genomics of breast cancer using the new molecular taxonomy
called “intrinsic subtypes of breast cancer” comprising of the luminal
subtypes A, B, and C; the basal-like subtype; the erbB-positive sub-
type; and the normal-like subtype. The intrinsic subtypes of breast
cancer predict patient relapse, overall survival, and response to endo-
crine and chemotherapy regimens. Triple-negative breast cancers,
characterized by the absence of estrogen receptors, progesterone re-
ceptors, and lack of overexpression of human epidermal growth fac-
tor receptor, are typically associated with poor prognosis and require
individual (personalized) strategies for treatment. Hereby, the com-
bination of histopathology with “omics” approaches—genomics,
transcriptomics, proteomics, and metabolomics—is an ongoing ef-
fort toward personalized medicine to identify new therapeutic targets
and bioimaging markers. For personalized medicine to be a success, it
is mandatory to use robust, multivariate, data analysis techniques and
algorithms to define, for the benefit of the patient, the molecular tu-
mor signature as a decision maker for individualized therapies.
R. Dalla-Favera (New York, NY). Lymphomas represent the fifth
most common type of human cancer. Non–Hodgkin lymphoma
consists mostly of B cells (85%), and only a minor part is presented
by T cells (15%). The risk to acquire a lymphoma seems to be the
price that has to be paid by human beings for producing high-affinity
antibodies during an inflammation process to be able to identify and
ultimately destroy foreign invaders. To establish the necessary level of
diversity, B- and T-cell receptor genes are created by recombining pre-
existing gene segments. This is accomplished by cleaving DNA with
specific, well-conserved recombination signal sequences. This highly
regulated step is carried out by the lymphocyte-specific recombination
activating genes (RAG1 and RAG2). The segments are then reassem-
bled using a common cellular repair mechanism. Fragile sites often
coincide with genes that are frequently rearranged or deleted in hu-
man cancers, including hematological disorders. BCL-6, a transcrip-
tional repressor frequently translocated in lymphoma, regulates
germinal center B-cell proliferation, differentiation, and inflamma-
tion. Blimp-1, a BCL-6 target, is important for plasmacytic differen-
tiation. Approximately 80% of B lymphomas have a constitutive
activation of nuclear factor κB and STAT3, which depends on up-
stream signaling through PI3K, and this activation is important for
cell survival and proliferation as well as for maintaining the level of
Myc. His group has also shown that BCL-6 encodes a BTB/POZ-
zinc finger transcriptional repressor that is necessary for germinal cen-
ter formation and the coactivator p300 binds and acetylates BCL-6
in vivo. Pharmacological inhibition of HDAC-dependent and SIR2-
dependent pathways, which controls BCL-6 acetylation, accumulates
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inactive, acetylated BCL-6, and leads to cell cycle arrest and apoptosis
in B-cell lymphoma.
Session V: Genetic Mutations/Clinical Implications
R. Gaynor (Indianapolis, IN), vice president for Product Develop-
ment and Medical Affairs, Oncology Business Unit, Eli Lilly, spoke
about the challenges in oncology drug development. The paradigm
of cytotoxic drug development has been transformed by those drugs
(Gleevec, Herceptin), which direct at specific molecular pathways
and are determined as driving forces of oncogenesis. Drug develop-
ment remains a slow and expensive process, with less than 10% of
molecules being tested in the clinic progressing to registration and
commercialization. The main cause of failure is not having matched
the right patient to the right compound, because of insufficient under-
standing of the mode of action of the drug, lack of predictive preclinical
models and biomarkers, issues in determining the optimal drug dose
and schedule, and the complexity of tumor biology. Identification of
predictive markers, which can serve as surrogates of response, should
increase clinical success rate. These measures, coupled with improved
clinical trial methods including adaptive designs, use of novel-novel
combinations, and patient enrichment strategies, are currently being
incorporated into clinical cancer trials to bring more rapidly needed
cancer drugs to patients.
E. Eisenhauer (Hamilton, Canada). There has been considerable
debate among experts about how best to undertake the clinical de-
velopment of targeted agents. Many have advocated the need for
changes to clinical trial design, including development of new end
points, strategies to identify predictive biomarkers and enrich trial
population, and changes to the usually discrete phase 1-to-2-to-3
transition to seamless movement between trial phases and adapting
the design to emerging results. The ultimate goal and emerging result
of a clinical trial should be an increase in survival rates and quality of
survival by a tested drug or combination of drugs. Within this context,
she addressed the term clinical benefit as a patient-centered or tumor-
centered end point. Clinical trials should use end points in a consistent
manner to enable clear communication between investigators, clini-
cians, and patients about the benefit of novel therapies (Eur J Cancer.
2009;45[13]:2249–2252).
D.G. Powe (Nottingham, UK). He introduced a targeted therapy
that adrenoceptor antagonists such as β-blocker drugs offer a novel
therapeutic strategy for retarding the progression of breast cancer. In vitro
studies and animal experiments showed that migration of tumor cells
can be regulated by the actions of norepinephrine (increase of cell
locomotion) and β-blocker drugs (decrease of cell locomotion) via target
adrenoceptors. An epidemiological retrospective study confirmed that
patients treated with β-blocker drugs (for preexisting hypertension)
showed a 57% reduced risk of distant metastasis formation (hazards
ratio = 0.430, 95% CI = 0.200-0.926; P = 0.031) and a 71% reduction
in breast cancer mortality after 10 years (hazards ratio = 0.291, 95%
CI = 0.119-0.715; P = 0.007) compared to breast cancer patients
not treated with β-blocker drugs (Oncotarget. 2010;1[7]:628–638).
The findings validate the potential for using adrenoceptor antagonists
as a new pharmacological approach to inhibit tumor progression in
breast cancer patients.
Q. Yu (Singapore, Singapore) spoke on epigenetic regulation of
targeted therapy. Cancer cells either show a gain of function (oncogene
activation) or a loss of function (loss of apoptosis). Epithelial-mesenchymal
transition (EMT) in cancer cells plays a pivotal role with respect to me-
tastasis formation. His group defined a critical role for the Forkhead
transcription factor FOXQ1 in regulating EMT in breast cancer cells.
FOXQ1 expression was correlated with high-grade basal-like breast
cancers and was associated with poor clinical outcome. RNAi-mediated
suppression of FOXQ1 expression in highly invasive human breast
cancer cells reversed EMT, reduced invasive ability, and alleviated other
aggressive cancer phenotypes manifested in three-dimensional Matrigel
cultures (Cancer Res. 2011; E-pub ahead of print). They also found that
miR-378-TOB2-cyclin D1 is a functional module to mediate the cross
talk between Myc and Ras signaling in cellular transformation.
S.Y. Rha (Seoul, Korea). Gastric cancer is a heterogeneous disease
that is not well detected by current tumor markers. Therefore, iden-
tifying molecular markers that can predict the potential for tumor
progression is important for appropriate individualized therapy. Using
the Cancer Metastasis Research Center microarray database (17K
cDNA microarray), they identified genes that were differentially ex-
pressed between 96 cancer and 98 normal gastric tissues; with the In-
genuity Pathway Analysis, they found 34 genes related to cancer.
Levels of one particular chemokine growth–regulated oncogene 1,
also named CXCL1, was found significantly higher in the serum of
GC patients compared to healthy donors (P = 0.05); within GC pa-
tients, CXCL1 serum levels increased accordingly to tumor stage and
lymph node metastasis. The CXCL1 gene seems to be a candidate
marker for GC progression.
K.S. Zaenker (Witten, Germany) gave the concluding remarks. He
summarized the key note findings of the speakers’ talks. Cancer can
break families, but cancer can also form families. The speakers and the
audience formed for 2.5 days a scientific and personalized treatment-
orientated family to learn more and exchange knowledge to fight can-
cer. There was good news, and there was bad news. The dysregulation
of 11 to 15 pathways poses an enormous challenge for cancer therapeu-
tics. This is a finite number; however, the mutational complexity on a
gene-by-gene level is still an eminent hurdle. As Ed Liu stated, every
cancer cell possesses some sets of driver and backseat driver mutations.
Once the crucial driver mutations in any given cancer have been iden-
tified, we will need to launch a hunt for targeted therapies against these
genes, their products, and the underlying regulation mechanism. As any
symposium of this scientific caliber, the outcome rests also on the
shoulders of financial supporters, the Fritz-Bender-Foundation (Munich,
Germany), the Genome Institute of Singapore (Singapore), and its in-
dustrial supporters and on the intellectual spirit and cooperation of the
audience. It was very much appreciated that many young students and
junior scientists attended the symposium. They were encouraged
through their participation in this meeting to enhance our common
endeavor for the dignity of patients.
202 Personalized Cancer Medicine 2011 Zaenker et al. Translational Oncology Vol. 4, No. 4, 2011
